Regulation of IL-1 receptor antagonist by TSH in fibrocytes and orbital fibroblasts

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages

  Li, Bin ^a   Smith, Terry J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MESSENGER RNA; THYROTROPIN;

ARTICLE; CELL STRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROBLAST; FIBROCYTE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HORMONE ACTION; HUMAN; HUMAN CELL; ORBIT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RNA STABILITY; UPREGULATION; WESTERN BLOTTING;

CELLS, CULTURED; FIBROBLASTS; GENE EXPRESSION REGULATION; GRAVES OPHTHALMOPATHY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; ORBIT; ORGAN SPECIFICITY; RNA STABILITY; THYROTROPIN;

EID: 84898417162     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3977     Document Type: Article

References (40)

1. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev . 2008;223:20-38.
2. . Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol . 2010;6:232-241.
3. Malyak M, Smith MF Jr, Abel AA, Hance KR, Arend WP. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J Immunol. 1998;161:2004-2010.
4. Butcher C, Steinkasserer A, Tejura S, Lennard AC. Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol . 1994;153:701-711.
5. Opp MR, Krueger JM. Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am J Physiol . 1991;260:R453-R457.
6. Romero R, Sepulveda W, Mazor M, et al. The natural interleukin-1 receptor antagonist in term and preterm parturition. Am J Obstet Gynecol . 1992;167:863-872.
7. Huang HY, Wen Y, Kruessel JS, Raga F, Soong YK, Polan ML. Interleukin (IL)-1- regulation of Il-1- and IL-1 receptor antagonist expression in cultured human endometrial stromal cells. J Clin Endocrinol Metab . 2001;86:1387-1393.
8. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev . 1998;19:673-716.
9. EndoT,OhnoM,Kotani S, Gunji K,OnayaT. Thyrotropin receptor in non-thyroid tissues. Biochem Biophys Res Commun . 1993;15: 774-779.
10. Feliciello A, Porcellini A, Ciullo I, Giulio B, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves disease retro-orbital tissue. Lancet . 1993;342:337-338.
11. ValyaseviRW,Erickson DZ, Harteneck DA, et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab . 1999;84: 2557-2562.
12. Herzog EL, Bucala R. Fibrocytes in health and disease. Exp Hermatol . 2010;38:548-556.
13. Douglas RS, Afifiyan NF, Hwang CJ, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab . 2010;95:430-438.
14. Fernando R, Atkins S, Raychaudhuri N, et al. Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci USA . 2012;109:7427-7432.
15. Bahn RS. Graves ophthalmopathy. N Engl J Med . 2010;362:726-738.
16. Smith TJ. Pathogenesis of Graves orbitopathy: a 2010 update. J Endocrinol Invest . 2010;33:414-421.
17. Li B, Smith TJ. Divergent expression of IL-1 receptor antagonists in CD34-fibrocytes and orbital fibroblasts in thyroid-associated ophthalmopathy: contribution of fibrocytes to orbital inflammation. J Clin Endocrinol Metab . 2013;98:2783-2790.
18. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest . 1997; 99:2930-2940.
19. Smith TJ. Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones. J Clin Invest . 1984;74:2157-2163.
20. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define anewleukocyte subpopulation that mediates tissue repair. Mol Med . 1994;1:71-81.
21. Bittencourt D, Auboeuf D. Analysis of co-transcriptionalRNAprocessing by RNA-ChIP assay. Methods Mol Biol . 2012;809:563-577.
22. Wang HS, Cao HJ, Winn VD, et al. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. J Biol Chem . 1996;271:22718-22728.
23. Gillespie EF, Papageorgiou KI, Fernando R, et al. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab . 2012;97:E740-E746.
24. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab . 2000;85:1194-1199.
25. Cao HJ, Han R, Smith TJ. Robust of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am J Physiol Cell Physiol . 2003;284:C1429-C1437.
26. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol . 1998;16: 27-55.
27. Evans I, Dower SK, Francis SE, Crossman DC, Wilson HL. Action of intracellular IL-1Ra (type 1) is independent of the IL-1 intracellular signalling pathway. Cytokine . 2006;33:274-280.
28. Levine SJ, Wu T, Shelhamer JH. Extracellular release of the type I intracellular IL-1 receptor antagonist from human airway epithelial cells: differential effects of IL-4, IL-13, IFN-, and corticosteroids. J Immunol . 1997;158:5949-5957.
29. Watson JM, Lofquist AK, Rinehart CA, et al. The intracellular IL-1 receptor antagonist alters IL-1 inducible gene expression without blocking exogenous signaling by IL-1-. J Immunol . 1995;155: 4467-4475.
30. Merhi-Soussi F, Berti M, Wehrle-Haller B, Gabay C. Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1- precursor on cell motility. Cytokine . 2005; 32:163-170.
31. Rettori V, Jurcovicova J, McCann SM. Central action of interleukin-1 in altering the release of TSH, growth hormone, and prolactin in the male rat. J Neurosci Res . 1987;18:179-183.
32. Dubois JM, Dayer JM, Siegrist-Kaiser CA, Burger AG. Human recombinant interleukin-1- decreases plasma thyroid hormone and thyroid stimulating hormone levels in rats. Endocrinology . 1988; 123:2175-2181.
33. Yamashita S, Kimura H, Ashizawa K, et al. Interleukin-1 inhibits thyrotrophin-induced human thyroglobulin gene expression. J Endocrinol . 1988;122:177-183.
34. Kung AW, Lau KS. Interleukin-1- modulates thyrotropin-induced thyroglobulin mRNA transcription through 3-5-cyclic adenosine monophosphate. Endocrinology . 1990;127:1369-1374.
35. Iwamoto M, Sakihama T, Kimura T, Tasaka K, Onaya T. Augmented interleukin-6 production by rat thyrocytes (FRTL5): effect of interleukin-1- and thyroid stimulating hormone. Cytokine . 1991;3:345-349.
36. Azuma H, Zeki K, Tanaka Y, et al. Inhibitory effect of IL-1 on the TSH dependent growth of rat thyroid cells (FRTL-5). Endocrinology . 1990;37:619-627.
37. Bartalena L, Manetti L, Tanda ML, et al. Soluble interleukin-1 receptor antagonist concentration in patients with Graves ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Clin Endocrinol (Oxf) . 2000;52:647-651.
38. Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol . 2000;2:197-202.
39. StanMN,Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid . 2013;23:620-625.
40. Neumann S, Eliseeva E, McCoy JG, et al. A new small-molecule antagonist inhibits Graves disease antibody activation of the TSH receptor. J Clin Endocrinol Metab . 2011;96:548-554.